Aurobindo Pharma Limited (AUROPHARMA)
Intimation of proposal of merger of two wholly owned stepdown subsidiaries with a wholly owned subsidiary.
Proposal approved for merger of two wholly owned step-down subsidiaries, Eugia Steriles and Eugia SEZ, into wholly owned subsidiary Eugia Pharma Specialities Limited.
- All entities manufacture injectable pharmaceutical products.
- FY26 turnover: Eugia Pharma 27.26bn INR, Eugia Steriles 62.7m INR, Eugia SEZ 4.87bn INR.
- Merger aims to simplify group structure and reduce costs.
- No cash consideration; shareholding unchanged.
- Transaction exempt from related party provisions under SEBI LODR and Companies Act.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 AUROPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add AUROPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Aurobindo Pharma Limited
Important.
The summary above is generated automatically from Aurobindo Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.